{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:11:05Z","timestamp":1778217065815,"version":"3.51.4"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Multimodal neuroimaging plays an indispensable role in the diagnosis, monitoring, and therapeutic evaluation of monoclonal antibody (mAb) therapies for Alzheimer's disease (AD). Structural MRI (sMRI) enables early detection of cerebral atrophy and amyloid-related imaging abnormalities (ARIA), a critical adverse effect associated with anti-A\u03b2 immunotherapies. Positron emission tomography (PET) provides direct visualization and quantification of A\u03b2 plaque clearance, serving as an objective biomarker of target engagement. Functional MRI (fMRI) has been investigated as a means to detect dynamic changes in brain network connectivity following treatment, though the evidence remains preliminary. The integration of these modalities significantly enhances diagnostic accuracy and allows for personalized assessment of treatment response. Furthermore, artificial intelligence (AI) technologies improve the efficiency and predictive power of imaging data analysis, supporting clinical decision-making. Despite these advances, challenges remain regarding the sensitivity and specificity of current imaging techniques, heterogeneity in treatment responses, and the need for long-term safety monitoring. Standardized imaging protocols, combined with multidisciplinary collaboration and robust AI-assisted modeling, are essential to optimize therapeutic outcomes and minimize risks in mAb-based AD treatment.<\/jats:p>","DOI":"10.3389\/fneur.2026.1761380","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:46:03Z","timestamp":1778215563000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The clinical value of multimodal neuroimaging in monoclonal antibody therapy for Alzheimer's disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Yingte","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Radiology, The Second Affiliated Hospital, Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Second Affiliated Hospital, Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Second Affiliated Hospital, Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saiyao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Second Affiliated Hospital, Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Airong","family":"Yang","sequence":"additional","affiliation":[{"name":"Qinghai Cardio-Cerebrovascular Specialty Hospital, Qinghai High Altitude Medical Research Institute","place":["Xining, Qinghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Second Affiliated Hospital, Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]},{"name":"Qinghai Cardio-Cerebrovascular Specialty Hospital, Qinghai High Altitude Medical Research Institute","place":["Xining, Qinghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.bbi.2023.12.026","article-title":"An immunological puzzle: the adaptive immune system fuels alzheimer's disease pathology","volume":"117","author":"Van Hoecke","year":"2024","journal-title":"Brain Behav Immun."},{"key":"B2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41377-021-00590-x","article-title":"Correlative optical photothermal infrared and X-ray fluorescence for chemical imaging of trace elements and relevant molecular structures directly in neurons","volume":"10","author":"Gustavsson","year":"2021","journal-title":"Light Sci Appl."},{"key":"B3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40035-025-00465-w","article-title":"Second-generation anti-amyloid monoclonal antibodies for alzheimer's disease: current landscape and future perspectives","volume":"14","author":"Kim","year":"2025","journal-title":"Transl Neurodegener."},{"key":"B4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","article-title":"Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer's disease therapeutics","volume":"83","author":"Cummings","year":"2023","journal-title":"Drugs."},{"key":"B5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","article-title":"Anti-amyloid monoclonal antibodies for the treatment of Alzheimer's disease","volume":"38","author":"Cummings","year":"2024","journal-title":"BioDrugs."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e70086","DOI":"10.1002\/alz.70086","article-title":"Lecanemab preferentially binds to smaller aggregates present at early alzheimer's disease","volume":"21","author":"Fertan","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13195-022-01110-8","article-title":"Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease","volume":"14","author":"Bateman","year":"2022","journal-title":"Alzheimers Res Ther."},{"key":"B8","unstructured":"Zhao\n              Z\n            \n            \n              Liu\n              Y\n            \n            \n              Ruan\n              S\n            \n            \n              Hu\n              Y\n            \n          \n          Current Anti-Amyloid-"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1093\/eurheartj\/ehad205","article-title":"Big tau aggregation disrupts microtubule tyrosination and causes myocardial diastolic dysfunction: From discovery to therapy","volume":"44","author":"Luciani","year":"2023","journal-title":"Eur Heart J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12987-023-00475-8","article-title":"Association between ventricular CSF biomarkers and outcome after shunt surgery in idiopathic normal pressure hydrocephalus","volume":"20","author":"Gronning","year":"2023","journal-title":"Fluids Barriers CNS."},{"key":"B11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1109\/JBHI.2021.3097721","article-title":"Task-induced pyramid and attention GAN for multimodal brain image imputation and classification in alzheimer's disease","volume":"26","author":"Gao","year":"2022","journal-title":"IEEE J Biomed Health Inform."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.medj.2024.08.004","article-title":"Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in alzheimer's disease","volume":"5","author":"Hu","year":"2024","journal-title":"Medicine."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e12503","DOI":"10.1002\/dad2.12503","article-title":"Validation of 3- and 5-point severity scales to assess ARIA-E","volume":"15","author":"Bracoud","year":"2023","journal-title":"Alzheimers Dement."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain."},{"key":"B15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s40478-025-02022-y","article-title":"Acute targeting of N-terminal tau protein has long-lasting beneficial effects in Tg2576 APP\/a\u03b2 mouse model by reducing cognitive impairment, cerebral a\u03b2-amyloidosis, synaptic remodeling and microgliosis later in life","volume":"13","author":"Latina","year":"2025","journal-title":"Acta Neuropathol Commun."},{"key":"B16","doi-asserted-by":"publisher","first-page":"136477","DOI":"10.1016\/j.ijbiomac.2024.136477","article-title":"CRM(197)-scaffolded vaccines designed by epitope grafting ameliorate cognitive decline in an alzheimer's disease model","volume":"281","author":"Cui","year":"2024","journal-title":"Int J Biol Macromol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.4103\/1673-5374.332127","article-title":"Amyloid-beta peptide and tau protein crosstalk in alzheimer's disease","volume":"17","author":"Roda","year":"2022","journal-title":"Neural Regen Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10654-020-00683-8","article-title":"Amyloid, tau and risk of alzheimer's disease: a mendelian randomization study","volume":"36","author":"Yeung","year":"2021","journal-title":"Eur J Epidemiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early alzheimer disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early alzheimer's disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2339337","DOI":"10.1080\/19420862.2024.2339337","article-title":"Reducing neonatal fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-beta antibody","volume":"16","author":"Schlein","year":"2024","journal-title":"MAbs."},{"key":"B22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41582-024-01053-8","article-title":"Amyloid-related imaging abnormalities: Manifestations, metrics and mechanisms","volume":"21","author":"Greenberg","year":"2025","journal-title":"Nat Rev Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e087613","DOI":"10.1002\/alz.087613","article-title":"The effect of VTA stimulation on hippocampal beta amyloid, tau protein accumulation and oxidative stress","volume":"20","author":"Bakhtiarzadeh","year":"2024","journal-title":"Alzheimer's Dement."},{"key":"B24","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1192\/bjp.2023.166","article-title":"Estimating demand for potential disease-modifying therapies for Alzheimer's disease in the UK","volume":"224","author":"Laurell","year":"2024","journal-title":"Br J Psychiatry."},{"key":"B25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s13195-024-01561-1","article-title":"High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for alzheimer's disease","volume":"16","author":"Arastoo","year":"2024","journal-title":"Alzheimers Res Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"101339","DOI":"10.1016\/j.arr.2021.101339","article-title":"Effects of monoclonal antibodies against amyloid-\u03b2 on clinical and biomarker outcomes and adverse event risks: a systematic review and meta-analysis of phase III RCTs in alzheimer's disease","volume":"68","author":"Avgerinos","year":"2021","journal-title":"Ageing Res Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00401-025-02890-7","article-title":"Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited alzheimer disease","volume":"149","author":"Chen","year":"2025","journal-title":"Acta Neuropathol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2217\/nmt-2022-0037","article-title":"The amyloid-\u03b2 pathway in alzheimer's disease: a plain language summary","volume":"13","author":"Hampel","year":"2023","journal-title":"Neurodegener Dis Manag."},{"key":"B29","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s13311-021-01026-5","article-title":"Recent advances in imaging of preclinical, sporadic, and autosomal dominant alzheimer's disease","volume":"18","author":"Buckley","year":"2021","journal-title":"Neurotherapeutics."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e14043","DOI":"10.1002\/alz.14043","article-title":"Precision diagnosis of cognitive impairment due to alzheimer's disease for therapeutic interventions","volume":"21","author":"Knopman","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/brain\/awad024","article-title":"Tilavonemab in early alzheimer's disease: results from a phase 2, randomized, double-blind study","volume":"146","author":"Florian","year":"2023","journal-title":"Brain."},{"key":"B32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.1109\/TMI.2020.3013825","article-title":"Disentangled-multimodal adversarial autoencoder: application to infant age prediction with incomplete multimodal neuroimages","volume":"39","author":"Hu","year":"2020","journal-title":"IEEE Trans Med Imaging."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2550043","DOI":"10.1142\/S0129065725500431","article-title":"An explainable connectome convolutional transformer for multimodal autism spectrum disorder classification","volume":"35","author":"Nazari","year":"2025","journal-title":"Int J Neural Syst."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1007\/s00259-025-07070-z","article-title":"Imaging biomarkers of cortical neurodegeneration underlying cognitive impairment in parkinson's disease","volume":"52","author":"Silva-Rodriguez","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e70061","DOI":"10.1002\/alz.70061","article-title":"Connectome-based predictive modeling of brain pathology and cognition in autosomal dominant alzheimer's disease","volume":"21","author":"Tripathi","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B37","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.1109\/JBHI.2023.3306460","article-title":"Individualized assessment of brain abeta deposition with fMRI using deep learning","volume":"27","author":"Li","year":"2023","journal-title":"IEEE J Biomed Health Inform."},{"key":"B38","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","article-title":"Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging","volume":"78","author":"Ossenkoppele","year":"2021","journal-title":"JAMA Neurol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"103006","DOI":"10.1016\/j.redox.2023.103006","article-title":"Therapeutic effects of long-term HBOT on alzheimer's disease neuropathologies and cognitive impairment in APP(swe)\/PS1(dE9) mice","volume":"70","author":"Yang","year":"2024","journal-title":"Redox Biol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"102681","DOI":"10.1016\/j.media.2022.102681","article-title":"From sMRI to task-fMRI: a unified geometric deep learning framework for cross-modal brain anatomo-functional mapping","volume":"83","author":"Zhu","year":"2023","journal-title":"Med Image Anal."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2174\/011570159X391766250806091602","article-title":"Structural and functional determinants of ARIA-H risk in anti-amyloid monoclonal antibodies: a comparative mechanistic framework for alzheimer's immunotherapy development","author":"An","year":"2025","journal-title":"Curr Neuropharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of solanezumab in preclinical alzheimer's disease","volume":"389","author":"Sperling","year":"2023","journal-title":"N Engl J Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.11477\/mf.1416202726","volume":"76","author":"Tomimoto","year":"2024","journal-title":"Brain Nerve."},{"key":"B44","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41582-025-01123-5","article-title":"Amyloid-lowering immunotherapies for alzheimer disease: current status and future directions","volume":"21","author":"Rafii","year":"2025","journal-title":"Nat Rev Neurol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e70288","DOI":"10.1002\/alz.70288","article-title":"The performance of plasma p-tau217 in black middle-aged and older adults","volume":"21","author":"Ennis","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B46","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13195-024-01600-x","article-title":"Blockade of brain alkaline phosphatase efficiently reduces amyloid-beta plaque burden and associated cognitive impairment","volume":"16","author":"Soria-Tobar","year":"2024","journal-title":"Alzheimers Res Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e1046","DOI":"10.1002\/ctm2.1046","article-title":"Monoclonal antibody-mediated immunosuppression enables long-term survival of transplanted human neural stem cells in mouse brain","volume":"12","author":"McGinley","year":"2022","journal-title":"Clin Transl Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"111028","DOI":"10.1016\/j.compbiomed.2025.111028","article-title":"Artificial intelligence for alzheimer's disease diagnosis through T1-weighted MRI: a systematic review","volume":"197","author":"Basanta-Torres","year":"2025","journal-title":"Comput Biol Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e70259","DOI":"10.1002\/alz.70259","article-title":"The down alzheimer barcelona neuroimaging initiative (DABNI) and its contributions to understanding alzheimer's disease in down syndrome: a decade of discovery","volume":"21","author":"Videla","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B50","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1001\/jamaneurol.2025.1232","article-title":"Lecanemab treatment in a specialty memory clinic","volume":"82","author":"Paczynski","year":"2025","journal-title":"JAMA Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"102276","DOI":"10.1016\/j.eclinm.2023.102276","article-title":"A neuroimaging biomarker for individual brain-related abnormalities in neurodegeneration (IBRAIN): a cross-sectional study","volume":"65","author":"Zhao","year":"2023","journal-title":"EClinicalMedicine."},{"key":"B52","doi-asserted-by":"publisher","first-page":"8937","DOI":"10.1002\/alz.14310","article-title":"Arterial spin labeling perfusion MRI in the alzheimer's disease neuroimaging initiative: past, present, and future","volume":"20","author":"Thropp","year":"2024","journal-title":"Alzheimers Dement."},{"key":"B53","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1109\/TMI.2024.3386937","article-title":"3D multimodal fusion network with disease-induced joint learning for early alzheimer's disease diagnosis","volume":"43","author":"Qiu","year":"2024","journal-title":"IEEE Trans Med Imaging."},{"key":"B54","doi-asserted-by":"publisher","first-page":"7320","DOI":"10.1002\/alz.14099","article-title":"The informatics of ADNI","volume":"20","author":"Toga","year":"2024","journal-title":"Alzheimers Dement."},{"key":"B55","doi-asserted-by":"publisher","first-page":"108564","DOI":"10.1016\/j.compbiomed.2024.108564","article-title":"Hierarchical attention-based multi-task and multi-modal fusion model for computer-aided diagnosis of alzheimer's disease","volume":"176","author":"Liu","year":"2024","journal-title":"Comput Biol Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"101618","DOI":"10.1016\/j.jksuci.2023.101618","article-title":"CsAGP: Detecting alzheimer's disease from multimodal images via dual-transformer with cross-attention and graph pooling","volume":"35","author":"Tang","year":"2023","journal-title":"J King Saud Univ Comput Inf Sci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"7407","DOI":"10.1038\/s41467-025-62590-4","article-title":"AI-driven fusion of multimodal data for alzheimer's disease biomarker assessment","volume":"16","author":"Jasodanand","year":"2025","journal-title":"Nat Commun."},{"key":"B58","doi-asserted-by":"publisher","first-page":"102834","DOI":"10.1016\/j.eclinm.2024.102834","article-title":"Development and validation of the florey dementia risk score web-based tool to screen for alzheimer's disease in primary care","volume":"76","author":"Pan","year":"2024","journal-title":"EClinicalMedicine."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e12286","DOI":"10.1002\/dad2.12286","article-title":"Effects of age, amyloid, sex, and APOE epsilon4 on the CSF proteome in normal cognition","volume":"14","author":"Wesenhagen","year":"2022","journal-title":"Alzheimers Dement."},{"key":"B60","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1093\/brain\/awae216","article-title":"Increases in amyloid-beta42 slow cognitive and clinical decline in alzheimer's disease trials","volume":"147","author":"Abanto","year":"2024","journal-title":"Brain."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1761380\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:46:07Z","timestamp":1778215567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1761380\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":60,"alternative-id":["10.3389\/fneur.2026.1761380"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1761380","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1761380"}}